NetworkNewsBreaks – BriaCell Therapeutics Corp.
Post# of 69
(Total Views: 199)
Posted On: 12/27/2018 5:08:46 PM
NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advancing Clinical Development of its Novel Advanced Breast Cancer Treatment
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company, is continuing its progression of Bria-IMT for the treatment of advanced breast cancer. An article discussing the company reads, “The Bria-IMT phase I/IIa monotherapy study involved 23 patients who were very heavily pre-treated (a median of four previous systemic therapy regiments per patient). The treatment with Bria-IMT was well-tolerated, with minor local irritation at the injection site being reported as the most common adverse effect. … More importantly, Bria-IMT contributed to tumor shrinkage in three of the patients. The top respondent previously received seven rounds of chemotherapy and had tumor metastases at various sites. The patient’s three-month follow-up showed shrinkage in all 20 metastatic formations in the lungs. After six months, the response was still maintained. Two other patients also showed tumor reduction. All of the patients with tumor reduction matched Bria-IMT at one or more HLA types, validating BriaCell’s approach to selecting patients most likely to respond (BriaDx). Biological activity was observed in several other of the patients, and there was a noted decrease in circulating cancer-associated cells.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company, is continuing its progression of Bria-IMT for the treatment of advanced breast cancer. An article discussing the company reads, “The Bria-IMT phase I/IIa monotherapy study involved 23 patients who were very heavily pre-treated (a median of four previous systemic therapy regiments per patient). The treatment with Bria-IMT was well-tolerated, with minor local irritation at the injection site being reported as the most common adverse effect. … More importantly, Bria-IMT contributed to tumor shrinkage in three of the patients. The top respondent previously received seven rounds of chemotherapy and had tumor metastases at various sites. The patient’s three-month follow-up showed shrinkage in all 20 metastatic formations in the lungs. After six months, the response was still maintained. Two other patients also showed tumor reduction. All of the patients with tumor reduction matched Bria-IMT at one or more HLA types, validating BriaCell’s approach to selecting patients most likely to respond (BriaDx). Biological activity was observed in several other of the patients, and there was a noted decrease in circulating cancer-associated cells.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)